Publications by authors named "Jan Demol"

Claim this Profile
S
Surveillance of Disease Progression in Metastatic Breast Cancer by Molecular Counting of Circulating Tumor DNA Using Plasma-SeqSensei Breast Cancer in Vitro Diagnostics Assay.
Geert A Martens, Jan Demol, Franceska Dedeurwaerdere, Kristof De Smet, Janusz Wesolowski

J Mol Diagn· January 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Abscopal effect in metastatic renal cell carcinoma.
Mieke Van de Walle, Jan Demol, Lorenzo Staelens, Sylvie Rottey

Acta Clin Belg· August 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
V
Virtual anatomical reconstruction of large acetabular bone defects using a statistical shape model.
Peter Vanden Berghe, Jan Demol, Frederik Gelaude, Jos Vander Sloten

Comput Methods Biomech Biomed Engin· May 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Computed tomography-based joint locations affect calculation of joint moments during gait when compared to scaling approaches.
Ward Bartels, Jan Demol, Frederik Gelaude, Ilse Jonkers, Jos Vander Sloten

Comput Methods Biomech Biomed Engin· August 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Modelling the effect of repositioning on the evolution of skeletal muscle damage in deep tissue injury.
Jan Demol, Dorien Van Deun, Bart Haex, Hans Van Oosterwyck, Jos Vander Sloten

Biomech Model Mechanobiol· April 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Towards a quantitative understanding of oxygen tension and cell density evolution in fibrin hydrogels.
Jan Demol, Dennis Lambrechts, Liesbet Geris, Jan Schrooten, Hans Van Oosterwyck

Biomaterials· January 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The effect of body mass index on overall and disease-free survival in node-positive breast cancer patients treated with docetaxel and doxorubicin-containing adjuvant chemotherapy: the experience of the BIG 02-98 trial.
Evandro de Azambuja, Worta McCaskill-Stevens, Prudence Francis, Emmanuel Quinaux, John P A Crown, Jan Demol

Breast Cancer Res Treat· January 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
Fulvestrant (Faslodex) in advanced breast cancer: clinical experience from a Belgian cooperative study.
Patrick Neven, Robert Paridaens, Gino Pelgrims, Marc Martens, Alain Bols, Jan Demol

Breast Cancer Res Treat· May 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phosphorylated HER-2 tyrosine kinase and Her-2/neu gene amplification as predictive factors of response to trastuzumab in patients with HER-2 overexpressing metastatic breast cancer (MBC).
Rosa Giuliani, Virginie Durbecq, Angelo Di Leo, Marianne Paesmans, Denis Larsimont, Jan Demol

Eur J Cancer· March 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A phase II study of sabarubicin (MEN-10755) as second line therapy in patients with locally advanced or metastatic platinum/taxane resistant ovarian cancer.
Francesco Caponigro, Pax Willemse, Roberto Sorio, Anne Floquet, Simon van Belle, Jan Demol

Invest New Drugs· January 2005

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis